RxDoctor Payments DataLook up a doctor →

Zeynep Eroglu, MD

Medical Oncology · Tampa, FLNPI 1760614739

Payments from drug & device makers

$30,929,522in general payments, 2019–2025

Across 680 payments — averaging $45,485 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$21M
  • Boehringer Ingelheim$3M
  • Novartis$2.3M
  • Merck$1.2M
  • E.r. Squibb & Sons, L.L.C.$786K
  • Genentech, Inc.$754K
  • plus $1.9M from 11 others
$17,128in research payments, 2019–2025

Across 81 payments — averaging $211.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$9K
  • Novartis$8K
  • Immunocore Limited$612

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$30,929,522 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$37,104
Medicare patients
189
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →